Citi upgrades Downer’s earnings forecasts and price target

Published 03-FEB-2017 12:41 P.M.


1 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Citi has responded positively to Downer EDI’s first half result which represented a significant outperformance against the broker’s forecasts at both the EBIT and net profit lines.

The engineering and construction group’s net profit of $78.2 million was more than 10% higher than Citi’s expectations of $70 million.

Furthermore, the broker pointed to management’s full-year profit upgrade from $163 million to $175 million (+7%) as representative of a positive outlook which warranted revisions of its earnings estimates and price target.

Citi upgraded its forecasts for fiscal years 2017 and 2018 by 7% and 9% respectively. Along with this strong performance, most analysts see the company entering a purple patch in 2018 as the level of activity in the infrastructure and utilities sectors accelerates.

Mining sector recovery could help Downer

While the downturn in the mining sector placed a drag on the company in recent years, the fact that the balance sheets of mining companies have strengthened substantially in the last 12 months suggests there could be investment in new projects, which would have a positive impact on Downer.

Citi increased its share price target from $6.15 to $7.30, and while this still represents a premium to yesterday’s closing price of $7.07 the broker has a neutral recommendation on the stock.

After the stock traded as high as $7.46 yesterday some technical analysts were suggesting that the company could be poised to push up towards $8.00 in the near term.

It should be noted that broker projections and price targets are only estimates and may not be met. Also, historical data in terms of earnings performance and/or share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free